Trials / Unknown
UnknownNCT02779699
A Study of AL2846 on Tolerance and Pharmacokinetics
Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.
Detailed description
To study the pharmacokinetic characteristics of AL2846 in the human body; To recommend a reasonable dose and indication for subsequent research.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 | AL2846 p.o. qd |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2016-05-20
- Last updated
- 2019-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02779699. Inclusion in this directory is not an endorsement.